Share Twitter LinkedIn Facebook Email Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 potentially shows promise in ovarian, metastatic prostate and pancreatic cancer. Advertisement
Alcohol Consumption and Cancer Risk: Insights from the 2025 Surgeon General’s Advisory Breast Cancer 3 Mins Read
